See your point about gray are, there are certainly a spectrum of possibilities. But if there’s any question on whether or not they achieve their endpoints, I believe the outcome will be ghastly for the stop price. I’m not sure there’s a scenario whereby efficacy is not certain for at least subtypes, and the company survives in its present form.